CSL and Alentis strike up to US$1.6 billion drug-development deal on October 05, 2026 Alentis Therapeutics Autoimmune Diseases Claudin-1 Drug Development Kidney Diseases lixudebart Primary sclerosing cholangitis SMPX gene +